Stanford Medicine: Taking on the Menopause, Breast Cancer Double Whammy

Tier 2: Professional organization or credentialed expert guidance
Publisher: Stanford Medicine · Published: August 20, 2026 · Accessed: September 4, 2026

Visit the source ↗

Claims this source supports

• About 16% of breast cancers are diagnosed before age 50, and about 80% of breast cancers carry receptors for estrogen and/or progesterone; people who survive hormone-receptor-positive cancers are advised to avoid hormone therapy.
• Kathryne Sanserino, MD (Stanford Medicine ob-gyn): for cancer survivors for whom hormone therapy is not an option, the HRT conversation 'lands differently... It feels like one more thing cancer took from them.'
• Options Stanford clinicians describe for survivors: fezolinetant (Veozah, FDA 2023) and elinzanetant (Lynkuet, FDA 2025); SSRI-class drugs; gabapentin; oxybutynin; low-dose vaginal estrogen after individual risk counseling (noting no RCT data in breast cancer survivors, only observational); plus lubricants, vaginal moisturizers, clinical hypnosis, and cognitive behavioral therapy.
• Named survivor story (Anu Gupta, 51, two-time breast cancer survivor, ER+/PR+): now manages symptoms with Lynkuet, an SSRI, and cognitive behavioral therapy tailored to insomnia, after earlier gabapentin gave partial relief.